Where is ERAS in the management of advanced ovarian cancer?: between myths and truths
- PMID: 36032026
- PMCID: PMC9428295
- DOI: 10.3802/jgo.2022.33.e79
Where is ERAS in the management of advanced ovarian cancer?: between myths and truths
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment on
-
Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups.J Gynecol Oncol. 2022 Sep;33(5):e60. doi: 10.3802/jgo.2022.33.e60. Epub 2022 Jun 3. J Gynecol Oncol. 2022. PMID: 35712972 Free PMC article.
References
-
- Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–108. - PubMed
-
- Lee YY, Lee JW, Lu L, Xu W, Kollara A, Brown T, et al. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynaecol Obstet. 2018;143:325–332. - PubMed
